Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.67 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972111 | 0.85 | PDE10A (0.51) | PDE10ATEKCSNK1A1CSNK1DGSK3B | |
| SCHEMBL972482 | 0.83 | PDE10A (0.67) | PDE10ATEKKDR | |
| SCHEMBL973999 | 0.81 | PDE10A (0.67) | PDE10ATEKKDR | |
| SCHEMBL972472 | 0.80 | PDE10A (0.71) | PDE10ATEK | |
| SCHEMBL974173 | 0.79 | PDE10A (0.72) | PDE10ATEKKDR | |
| SCHEMBL974773 | 0.74 | PDE10A (0.60) | PDE10ATEKGSK3BKDR | |
| SCHEMBL15850437 | 0.73 | NUDT1 (0.47) | PDE10ACSNK1A1KDRNUDT1 | |
| SCHEMBL2489750 | 0.72 | PDE10A (0.63) | PDE10ATEK | |
| SCHEMBL580118 | 0.72 | AURKA (0.65) | PDE10ACSNK1D | |
| SCHEMBL973068 | 0.72 | TEK (0.70) | PDE10ATEKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | PDE10A 2613/4885TEK 22/4885CSNK1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.